
Callinex to Advance its Gold Rich Point Leamington Base Metals Deposit in Newfoundland
Open Pit-Constrained Mineral Resource Estimate in Indicated category of 5.0 Mt of 2.49 g/t AuEq and Inferred category of 13.7 Mt of 2.24 g/t AuEq;
Out-of-Pit Mineral Resource Estimate in Inferred category of 1.7 Mt grading 3.06 g/t AuEq which is open for expansion;
The last exploration drilling campaign in 2004 intersection, at depth 4.67m of 4.37 g/t Au, 15.05% Zn, 57.88 g/t Ag and 0.36% Cu;
New metallurgical team will confirm recovery of copper and zinc and will refine an economic path to recover gold; and
The Company intends to complete an exploration campaign to grow the high-grade mineralization, test newly defined high priority targets and collect samples to complete mineralogical studies and metallurgical testwork.
VANCOUVER, BC, April 29, 2025 /CNW/ - Callinex Mines Inc. (the "Company" or "Callinex") (TSXV: CNX) (OTCQX: CLLXF) is pleased to announce plans to advance the Company's 100% owned Point Leamington Deposit, Newfoundland (the "Project"). This Project hosts a volcanogenic massive sulphide ("VMS") deposit (the "Deposit"), which contains significant gold, copper, zinc and silver mineralization and is open for expansion (Pt. Leamington Deposit 3D View). The Deposit is located within a mineral lease and is accessible by road followed by trails and is approximately 37km from the city of Grand Falls-Windsor and is also 20km from the Newfoundland hydroelectric power grid (Pt. Leamington Project Area Overview). Investors are invited to view a pre-recorded webinar detailing the exploration objectives outlined below by viewing: Callinex 2025 Pt. Leamington Deposit Exploration Overview
Max Porterfield, President & CEO of Callinex Mines stated, "Point Leamington is a large, near surface VMS deposit in the mining friendly province of Newfoundland that has a considerable gold resource in addition to copper, zinc and silver. Given the significant rise in metal prices, in particular gold, the intrinsic value of the Point Leamington deposit has risen dramatically overall and in relation to other deposits Callinex possesses." Mr. Porterfield continued, "Additionally, Callinex has strengthened our team with expertise to maximize value at Point Leamington and other projects within the Company's robust portfolio. We plan to aggressively advance this Project with an exploration campaign to expand the known resource and discover new deposits on the broader land package in tandem with mineralogical and metallurgical test work."
Table 1.1 Point Leamington Resource Estimate Grade
Table 1.2 Point Leamington Resource Estimate Contained Metal
1.
Mineral Resources, which are not Mineral Reserves, do not have demonstrated economic viability.
2.
The estimate of Mineral Resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues.
3.
The Inferred Mineral Resource in this estimate has a lower level of confidence than that applied to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that the majority of the Inferred Mineral Resource could be upgraded to an Indicated Mineral Resource with continued exploration.
4.
The Mineral Resources in this Technical Report were estimated using the Canadian Institute of Mining, Metallurgy and Petroleum (CIM), CIM Standards on Mineral Resources and Reserves, Definitions and Guidelines prepared by the CIM Standing Committee on Reserve Definitions and adopted by the CIM Council (2014) and CIM Best Practices Guidelines (2019).
5.
The Mineral Resource Estimate was based on August 2021 consensus economics forecast metal prices of US$1,625/oz gold, US$22/oz silver, US$3.50/lb copper, US$1.20/lb. Zinc.
6.
Additional details of the Mineral Resource Estimate, including the parameters and assumptions, are set forth in the Company's news release dated October 25, 2021.
The Company's exploration portfolio hosts several base and precious metals rich VMS deposits strategically located within known mining districts across Canada. The portfolio provides exposure to underlying metal prices, which in an escalating price environment, can have a significant material impact on the value of each specific deposit. Over the last several years Callinex has quietly continued to work on the Point Leamington Project in preparation to advance it at an optimum time. The strong up-move in gold prices over the last year makes now a great time to renew our focus on this Deposit.
Exploration Opportunities
There is an opportunity to significantly expand a higher-grade zone of the Deposit with additional drilling at depth. The most recent hole drilled in 2004, PL04-077, intersected 4.67m grading 4.37 g/t Au, 15.05% Zn, 57.88 g/t Ag and 0.36% Cu and PL-056 intersected 4.51m grading 2.27 g/t Au, 8.84% Zn, 81.66 g/t Ag and 0.61% Cu, which are the two deepest holes to intersect the Deposit. Drill holes PL04-077 and PL-056 are located 150 metres apart and the Deposit is open for extension below the 435 metre level (Pt. Leamington 3D Long Section).
The Deposit also has potential to host additional tonnage along strike. Drill hole PL04-073, drilled during the 2004 exploration campaign, intersected 3.9m grading 1.65 g/t Au, 5.18% Zn, 33.1 g/t Ag and 0.27% Cu (Pt. Leamington Deposit Long Section). The Company is currently reprocessing historic borehole pulse electromagnetic data surrounding the largely untested area and additional drilling may be completed in the future.
The Point Leamington Deposit style of mineralization, alteration, and host rocks suggests that it is a Kuroko-type VMS deposit hosted in Cambro-Ordovician age rocks, which are similar to the past producing Buchans and Duck Pond Mines in the Point Leamington area. The massive sulphides occur at a transitional period between altered felsic volcanics (dominantly flows, breccias, and pyroclastic) and a sedimentary / mafic volcanic sequence. As a result of reviewing historical regional data, the Company believes that there is significant opportunity to discover additional deposits with further exploration efforts.
Additionally, Callinex's larger exploration land package at the Project includes a number of untested geophysical anomalies within favorable geologic units that will be further refined with plans to be drilled. These target areas have been identified after reviewing Callinex's proprietary exploration database including over 2,400 line-kilometers of modern airborne electromagnetic survey data with a focus on nearby areas with a similar geological setting as the Deposit.
Gold, Copper and Zinc Mineral Processing
Callinex has engaged a leading consulting firm with a core expertise in the economic metallurgical recovery of gold, to oversee and manage metallurgical work at the Deposit moving forward. From a review of prior mineralogical studies and metallurgical test work, a process will be put in place to confirm recovery of copper and zinc as well as a promising processing route has been identified for the recovery of gold from the Deposit.
The Company plans to collect representative samples from both identified gold zones in the Deposit, to be used initially for a detailed mineralogical study. These samples will be used in a bench scale metallurgical test program, involving a flotation program to recover copper and zinc, separate arsenopyrite from pyrite, and to recover liberated gold. The bench scale test work is expected to be confirmed by a test program in a respected commercial lab. Gold concentrate produced will be processed with a focus on leach alternatives to maximize gold recovery or sold in the open market. The results of this multi-phase metallurgical program will be used to generate a preliminary economic evaluation of the entire Project.
The Company also intends to complete an up to 5,000 meter exploration campaign at the Project to grow the high grade mineralization associated with the deposit, test newly identified high priority targets and collect samples to complete mineralogical studies and metallurgical testwork for the economic recovery of the metals with a particular focus on gold.
Callinex's Engagement of ICP Securities Inc.
Further the Company's news release on February 27, 2025 announcing the engagement of ICP Securities Inc. ("ICP"), the Company confirms that, at the time of the engagement, ICP did not hold any securities of the Company.
Qualified Person
The technical information contained in this news release has been reviewed and approved by Aaryn Hutchins, P. Geo, a qualified person under NI 43-101. Ms. Hutchins is a consultant of the Company and is independent of the Company. Historical information was verified from geological reports filed with the government by previous operators.
Point Leamington Project
The Point Leamington Project, consisting of Mining Lease 136 (2655), is located approximately 37km by road and trails from the City of Grand Falls-Windsor and approximately 20km from the provincial power grid. The Deposit is a large, felsic-hosted VMS deposit that dips 70 degrees to the west, has a strike length of 500m and a maximum thickness of 85m. Massive sulphides have been intercepted to a depth of 360m below surface from a total of approximately 21,714m of drilling in 72 drill holes. Regional government mapping and lithogeochemical sampling has indicated that Point Leamington's host volcanic stratigraphy extends well beyond the vicinity of the Deposit.
About Callinex Mines Inc.
Callinex Mines Inc. (TSXV: CNX) (OTC: CLLXF) is advancing its portfolio of base and precious metals rich deposits located in established Canadian mining jurisdictions. The focus of the portfolio is highlighted by the rapidly expanding Rainbow deposit at its rich VMS Pine Bay Project located near existing infrastructure in the Flin Flon Mining District. Callinex prepared an indicated mineral resource on the Rainbow deposit of 3.44 Mt grading 3.59% CuEq for 272.4 Mlb CuEq (238.3 Mlb Cu, 56.9 Mlb Zn, 37.6 koz Au, 692.8 koz Ag, 2.3 Mlb Pb), an inferred mineral resource on the Rainbow deposit of 1.28 Mt grading 2.95% CuEq containing 83.4 Mlb CuEq (72.1 Mlb Cu, 19.5 Mlb Zn, 11.1 koz Au, 222.2 Koz Ag, 0.8 Mlb Pb) and an inferred mineral resource at the Pine Bay deposit of 1.0 Mt grading 2.62% Cu containing 58.1 Mlb Cu (see news release dated July 10, 2023). The second asset in the portfolio is the Nash Creek Project located in the VMS rich Bathurst Mining District of New Brunswick. A 2018 PEA generates a strong economic return with a pre-tax IRR of 34.1% (25.2% post-tax) and NPV8% of $230 million ($128 million post-tax) at $1.25 Zinc (see news release dated May 14, 2018). The third asset, 100% owned Point Leamington Deposit in Newfoundland, is located in one of the richest VMS and Gold Districts in Canada. Callinex prepared a pit constrained Indicated Mineral Resource of 5.0 Mt grading 2.5 g/t AuEq for 402 koz AuEq (145.7 koz gold, 60.0 Mlb copper, 153.5 Mlb zinc, 2.0 Moz silver, 1.5 Mlb lead), a pit constrained Inferred Mineral Resource of 13.7 Mt grading 2.24 g/t AuEq for 986.5 koz AuEq (354.8 koz gold, 110.2 Mlb copper, 527.3 Mlb zinc, 6.2 Moz silver, 7.0 Mlb lead) and an out-of-pit Inferred Mineral Resource of 1.7 Mt grading 3.06 g/t AuEq for 168.5 koz AuEq (65.4 koz gold, 13.3 Mlb copper, 102.9 Mlb zinc, 1.4 Moz Ag, 2.6 Mlb lead) (see news release dated October 25, 2021).
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Some statements in this news release contain forward-looking information. These statements include, but are not limited to, statements with respect to future expenditures. These statements address future events and conditions and, as such, involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the statements. Such factors include, among others, the ability to complete the proposed drill program and the timing and amount of expenditures. Except as required under applicable securities laws, Callinex does not assume the obligation to update any forward-looking statement.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Cision Canada
an hour ago
- Cision Canada
AWE2026 Officially Launched: Two Venues, One Vision to Reshape the Industry Landscape
SHANGHAI, July 22, 2025 /CNW/ -- On July 22, the China Household Electrical Appliances Association held the official launch event for the 2026 Appliance & Electronics World Expo (AWE2026) in Shanghai. Under the theme "Smart AI, Smarter Future," AWE2026 will introduce a brand-new dual-venue format, with the exhibition running March 12-15, 2026, across two locations: the Shanghai New International Expo Center and the Sunrise Complex at the Shanghai Eastern Hub International Business Cooperation Zone. It is expected to span over 170,000 square meters, feature more than 1,200 leading brands, and draw over 200,000 attendees. AWE2026 will showcase cutting-edge innovations in smart technology and immersive future lifestyle solutions from around the world, reinforcing its role as a global hub for technological advancement and industry collaboration. The two AWE2026 venues will work in close coordination, complementing each other in both focus and function. The Shanghai New International Expo Center zone will run for four days, from March 12 to 15, 2026, with the final day dedicated as Consumer Day. This zone will continue to gather over a thousand leading global brands and innovators from across the home appliance and consumer electronics value chain. Spanning 140,000 square meters, it will showcase smart living solutions and cutting-edge products, featuring innovations in whole-home intelligence, digital entertainment, fitness and health, green energy, smart mobility, smart office, smart cities, and more - presenting a comprehensive view of an industry evolving around people and real-life scenarios. The Shanghai Eastern Hub International Business Cooperation Zone is designated as the Advanced Consumer Electronics Technology Zone, running for three days from March 12 to 14, 2026. Located on the third floor of the Sunrise Complex within the zone, this 30,000-square-meter area will focus on cutting-edge fields such as chip and computing technologies, AI, next-generation information technologies, new display technologies, robotics, drones, new energy vehicles, and smart home solutions. The zone will be organized into four themed areas: breakthroughs in core technologies, commercialization of innovative products, upgrades of intelligent digital terminals, and smart lifestyle scenarios—showcasing the new quality productive forces driving the consumer electronics industry in the AI era. With broader vision, stronger momentum, and a more open stance, AWE will continue to empower global innovation, stimulate new consumption vitality, and lead the industry into a new era of smart living driven by AI. See you in Shanghai, March 12-15, 2026!


Toronto Star
3 hours ago
- Toronto Star
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units ('Units'), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the 'Offering').


Globe and Mail
3 hours ago
- Globe and Mail
XORTX Completes Non-Brokered Private Placement of Units
Not For Distribution to United States News Wire Services or for Dissemination in the United States CALGARY, Alberta, July 22, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (' XORTX ' or the ' Company ') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to announce the closing of its previously announced non-brokered private placement of units (' Units '), whereby it issued 1,267,123 Units at a price of US$0.73 per Unit for aggregate gross proceeds of US$925,000 pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (the ' Offering '). Under the Offering, each Unit consisted of one common share in the capital of the Company (' Common Share ') and one common share purchase warrant (' Warrant '). Each Warrant entitles the holder thereof to purchase one additional Common Share at a price of US$1.20 for a period of sixty (60) months following the date of issuance provided, however, that if the closing price of the Common Shares on the Nasdaq is greater than US$2.00 for ten (10) or more consecutive trading days, the Warrants will be accelerated and will expire on the 30 th business day following the date of such notice. Closing of the Offering was approved by the TSX Venture Exchange (' TSXV '), and the securities issued under the Offering will not be subject to a four-month and one-day statutory hold period. The Company intends to use the proceeds of the Offering as more specifically described in the Offering Document and for gout programs, general corporate and working capital purposes. In connection with the Offering, the Company paid an aggregate of $12,264 in finder's fees and issued, in aggregate, 16,800 finder's warrants. The securities have not and will not be registered under the U.S. Securities Act of 1933, as amended (the ' U.S. Securities Act '), or any applicable state securities laws and may not be offered or sold to, or for the account or benefit of, persons in the United States or 'U.S. persons,' as such term is defined in Regulation S promulgated under the U.S. Securities Act, absent registration or an exemption from such registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The issuance of 8,191 Units to an insider of the Company constitutes a 'related party transaction' as such term is defined in Multilateral Instrument 61-101 – Protection of Minority Securityholders in Special Transactions (' MI 61-101 '). Pursuant to Sections 5.5(a) and 5.7(1)(a) of MI 61-101, the Company relied on exemptions from the formal valuation and minority shareholder approval requirements, respectively, as neither the fair market value of the Units nor the consideration for such Units, insofar as it involves the insider, exceeds 25 percent of the Company's market capitalization. In other news, the non-brokered private placement that was announced on May 19, 2025 will not proceed. About XORTX Therapeutics Inc. XORTX is a pharmaceutical company with three clinically advanced products in development: 1) our lead program XRx-026 program for the treatment of gout; 2) XRx-008 program for ADPKD; and 3) XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type 2 diabetic nephropathy. XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications that improve the quality of life and health of individuals with gout and other important diseases. Additional information on XORTX is available at For more information, please contact: Forward-Looking Statements Statements contained in this news release that are not historical facts are 'forward-looking information' or 'forward-looking statements' within the meaning of applicable Canadian securities laws. Such forward-looking statements or information are provided to inform the Company's shareholders and potential investors about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Any such forward-looking information may be identified by words such as 'anticipate', 'proposed', 'estimates', 'would', 'expects', 'intends', 'plans', 'may', 'will', and similar expressions, although not all forward-looking information contains these identifying words. More particularly and without limitation, the forward-looking information in this news release includes (i) expectations regarding the Company's current and future financing plans; (ii) expectations concerning the Company's plans and objectives in respect of the Offering's gross proceeds; and (iii) expectations regarding the Company's business plans and operations. Forward-looking information is based on a number of factors and assumptions that have been used to develop such information, but which may prove to be incorrect and are inherently subject to significant business, economic and competitive uncertainties, and contingencies. The material factors and assumptions used in preparing the forward-looking information contained herein include, among others, our ability to obtain additional financing; the accuracy of our estimates regarding expenses, future revenues and capital requirements; the success and timing of our preclinical studies and clinical trials; the performance of third-party manufacturers and contract research organizations; our plans to develop and commercialize our product candidates; our plans to advance research in other kidney disease applications; and our ability to obtain and maintain intellectual property protection for our product candidates. Although the Company believes that the expectations reflected in such forward-looking information are reasonable, undue reliance should not be placed on forward-looking information because the Company can give no assurance that such expectations will prove to be correct. The forward-looking information in this news release reflects the Company's current expectations, assumptions and/or beliefs based on information currently available to the Company. Any forward-looking information speaks only as of the date on which it is made and, except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any forward-looking information, whether as a result of new information, future events or results or expressly qualified by this cautionary statement. More detailed information about the risks and uncertainties affecting XORTX is contained under the heading 'Risk Factors' in XORTX's Annual Report on Form 20-F filed with the SEC, which is available on the SEC's website, (including any documents forming a part thereof or incorporated by reference therein), as well as in our reports, public disclosure documents and other filings with the securities commissions and other regulatory bodies in Canada, which are available on Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.